Prior authorization & UM · Clinical NLP for PA / UM
Hindsait
Hindsait applies clinical NLP and document intelligence to prior authorization and utilization-management review for plans and related organizations. It is not a clinic-side portal automation product.
Strong fit
- Health plans, Medicare contractors, and review teams reading free-text charts for prior authorization and medical necessity
- Groups that need evidence matched to MCG, InterQual, or plan rules in a form that holds up in an audit
- Buyers who track review minutes per case and how consistent first decisions are
Weak fit
- Small clinics that only need help submitting to a few payers' portals
- Buyers looking for a full claims clearinghouse or patient billing product
- Teams that will not keep clinicians involved in complex decisions
Bottom line
Hindsait is worth using for health plan and Medicare contractor teams whose prior authorization and clinical reviews still stall on unstructured charts. It suits teams with guideline libraries and strong patient data controls. Buyers who want a full payer utilization management suite may prefer Xsolis or Agadia.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Hindsait is a clinical AI company in Hackensack, New Jersey, founded in 2013. The company is small, with fewer than 15 people.
It turns free-text medical records into organized evidence for prior authorization, utilization management, and other clinical reviews. It is in use at WPS Health, and Gartner recognized it in 2026 for intelligent prior authorization.
It is not a tool for filling out provider portals like Valer.
Customers see shorter reviews and more consistent matching to criteria when its language processing fills in review worksheets, instead of staff searching through free text.
Getting it running needs an owner in utilization management, guideline libraries, controls for patient data, and real effort to change how people work. Prices are quoted for each customer.
Among prior authorization tools we review, Hindsait scores below Xsolis and Agadia overall, as a narrower tool focused on clinical review. It scores above Rhyme on clinical depth.
Xsolis or Agadia suit buyers who want a full payer utilization management suite. Careviso suits lab and specialty submissions, and Infinitus suits teams whose bottleneck is phone time with payers.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Anterior | 8.1 | 8.1 |
| Xsolis | 7.8 | 7.3 |
| Infinitus | 7.7 | 7.4 |
| Humata Health | 7.7 | 7.4 |
| Agadia | 7.6 | 7.2 |
| Careviso | 7.6 | 7.3 |
| Silna Health | 7.3 | 7.1 |
| Itiliti Health | 7.3 | 7.1 |
| Banjo Health | 7.2 | 7.0 |
| Hindsait | 7.0 | 6.7 |
| Rhyme | 6.5 | 6.3 |
Pricing
| Item | Detail |
|---|---|
| Model | A clinical AI platform for prior authorization, utilization management, and related reviews, with quoted prices. |
| What usually drives cost | The number of cases, which modules you buy (prior authorization, utilization management, payment integrity), cloud or on-premise setup, and services. |
| What to ask before you buy | The cost per review or the yearly fee at your monthly review volume, and which cases a person still checks. |
| Published pricing | Hindsait does not publish prices. Expect pricing based on volume. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Hindsait to function | |
| A named prior authorization or access lead who can change how submissions work | Software with no owner goes unused. |
| Current numbers for authorization turnaround, denials, and abandoned orders | You cannot show value without a starting number. |
| A written list of data coming from the EHR, ordering, or practice management systems | Missing data sends staff back to retyping into payer portals. |
| A staffing plan for problem cases after launch | Problem cases no one owns turn into delayed care. |
| A list of the payers and services with the most prior authorizations | A generic setup misses where you really get stuck. |
| What will maximize your value | |
| Track the typical days to authorization every week for 90 days | Counting logins does not show results. |
| Start with one specialty or one lab | A small real win is worth more than a broad launch with nothing behind it. |
| Drop duplicate tracking spreadsheets after one month running both | Entering everything twice doubles the cost. |
| Review stuck cases in a regular short meeting | Unpaid balances that quietly grow older hide problems. |
| Send clinical and finance leaders a monthly access summary | Delays no one reports surprise everyone later. |
| Deal-breakers | |
| No one will own prior authorization problem cases. | |
| You will not do the connection or enrollment work it needs. | |
| You expect a prior authorization tool to replace your EHR. | |
| Leaders will not measure how long authorizations take. | |
| Your compliance team blocks the data sharing that submissions need. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Plan and measure the starting point | 2-4 weeks. Agree on measures, list payers, and list data sources. |
| 2 | Set up | 4-10 weeks. Build rules, templates, and connections, and test real cases. |
| 3 | Pilot | 2-6 weeks. Run one specialty or site and write down how to handle problem cases. |
| 4 | Expand | 1-3 months. Add payers and sites, and stop using side trackers. |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.